Navigation Links
Phlo Affiliate Names Director Of Marketing
Date:11/7/2007

JACKSONVILLE, Fla., Nov. 7 /PRNewswire-FirstCall/ -- An affiliate of Phlo Corporation (OTC: PHLC) (the "Company") announced today that it has hired Dan Reynolds as its Director of Marketing. Mr. Reynolds is a marketing and communications expert with nearly 30 years of experience in the United States and Canada. Mr. Reynolds will support the branding, marketing, and communications functions of the Company, headed by Rudy Prajza, Chief Marketing Officer.

Mr. Reynolds' professional experience includes work in over 14 industries such as food and beverages, financial services, hospitality, telecommunications, automobiles, health and beauty aids, and petroleum. His direct working experience includes such internationally-recognized organizations as Gillette, Subway, Sears, Royal Bank, BMW, Honda, the Government of Canada, Brita (water purifiers), and Petro-Canada, among others.

Mr. Reynolds has worked with a number of marketing communications companies including Saatchi & Saatchi, DMB&B, Foote, Cone & Belding, and MacLaren-McCann Advertising.

AQUISS(TM) features the Company's Instant Nano Hydration and Cell Armor technologies, providing instant, direct delivery of rehydration and cell- repair-and-protection payloads into the bloodstream beginning through the membranes of the mouth. These Instant Nano Hydration and Cell Armor technologies help provide sustained wellness necessary for life's performances and vigorous longevity. In addition, the Company's nano-encapsulation technology prevents the destruction of its active payloads in the stomach.

Phlo is a biotechnology company and a manufacturer and marketer of products (primarily liquids) containing patented and patent-pending biotechnologies. Phlo is focusing its technology generation and acquisition efforts on those technologies related to enhancing cognition and personal performance, reducing the effects of aging, and preventing or ameliorating cancer.

Certain statements made herein that are not historical constitute "forward-looking" statements within the meaning of the Private Litigation Reform Act of 1995 and may contain words such as "anticipate," "believe," "expect," "future," "may," "will," "should," "plan," "projected," "intend," and similar expressions to identify such forward-looking statements. Such statements are based on a number of assumptions and on information and estimates supplied to Phlo Corporation by sources currently available to it. Such assumptions and estimates are subject to uncertainties, contingencies, and other factors, many of which are beyond Phlo Corporation's control. Actual results may differ materially from the statements set forth above.


'/>"/>
SOURCE Phlo Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Phlo Affiliate Reports Expanded Coverage to Oregon Border
2. Phlo Affiliate Reports AQUISS to be Sold in 450 7-Eleven Stores
3. Phlo Affiliate Hires Chief Marketing Officer With Extensive Global Experience
4. Phlo Affiliate to Launch AQUISS(TM) on East Coast
5. KGI Names Kerry Howell Vice President for Advancement
6. Vical Names Andrew de Guttadauro Vice President, Corporate Development
7. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. CryoLife Names Philip Theodore as Vice President, General Counsel
10. Genstar Names Michael Hurt to Its Strategic Advisory Board
11. PPD Names Daniel Darazsdi as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
(Date:6/23/2016)... Prostate Cancer Foundation (PCF) is pleased to announce 24 new Young ... cancer. Members of the Class of 2016 were selected from a pool of ... More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case ... Denmark detail how a patient who developed lymphedema after being treated for breast cancer ... could change the paradigm for dealing with this debilitating, frequent side effect of cancer ...
Breaking Biology Technology:
(Date:6/9/2016)... leader in attendance control systems is proud to announce the introduction of fingerprint attendance ... the right employees are actually signing in, and to even control the opening of ... ... ... Photo - ...
(Date:6/2/2016)... The Department of Transport Management (DOTM) of ... Dollar project, for the , Supply and Delivery ... IT Infrastructure , to Decatur ... Identity Management Solutions. Numerous renowned international vendors participated in the ... was selected for the most compliant and innovative solution. The ...
(Date:5/24/2016)... , May 24, 2016 Ampronix facilitates superior patient care by providing ...  3D medical LCD display is the latest premium product recently added to the range ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
Breaking Biology News(10 mins):